Navigation Links
Novavax Announces Closing of $18 Million Registered Direct Offering
Date:8/1/2008

inant proteins.

Novavax's VLPs resemble a virus but lack the genetic material that would cause infection. Using the Company's proprietary VLP technologies, Novavax is developing vaccines to protect against H5N1 pandemic influenza, seasonal flu and other viral diseases. The Company also utilizes a unique portable manufacturing system that allows for rapid production of vaccines requiring less infrastructure and represents a potential simpler and more efficient approach to vaccine production. Additional information about Novavax is available at http://www.novavax.com and in the Company's various filings with the SEC.

Forward Looking Statements Statements herein relating to future financial or business performance, conditions or strategies and other financial and business matters, including expectations regarding revenues, operating expenses, cash burn, and clinical developments and anticipated milestones are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks and uncertainties, including the Company's ability to progress any product candidates in preclinical or clinical trials; the scope, rate and progress of its preclinical studies and clinical trials and other research and development activities; the results of clinical trials; even if the data from preclinical studies or clinical trials is positive, the product may not prove to be safe and efficacious; Novavax's pilot plant facility is subject to extensive validation and FDA inspections, which may result in delays and increased costs; the effect or outcome of the Company's decision to sell Estrasorb(R); the human c
'/>"/>

SOURCE Novavax, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Novavax CEO to Present at BIO CEO & Investor Conference
2. Novavax Enters Into Estrasorb(R) Asset Sale and Supply Agreements with Graceway Pharmaceuticals, LLC
3. Graceway Pharmaceuticals, LLC(TM) Announces Completed Acquisition of All Assets Related to Estrasorb(R) Product Line in North America From Allergan, Inc. (NYSE: AGN) and Novavax, Inc. (Nasdaq: NVAX)
4. Novavax CEO to Present at the World Vaccine Congress 2008
5. Novavax Opens Its First U.S. Vaccine Plant
6. Novavax Announces Release Date of 2008 First Quarter Financial Results and Investor Conference Call
7. Novavax Reports First Quarter 2008 Financial Results
8. Novavax CEO to Present at ACUMENBioFins 5th Annual Global Healthcare Conference
9. Novavax CEO to Present at FBR Capital Markets 12th Annual Spring Investor Conference
10. Novavax CEO to Present at Piper Jaffray Europe Conference, London, UK
11. Novavax to Join Russell 3000 Index
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... Hutchison China MediTech Limited ... (publ) ("AstraZeneca"), Hutchison MediPharma Limited,s ("HMP") collaboration partner, ... clinical trial of HMP,s c-Met inhibitor savolitinib (AZD6094) ... cell lung cancer ("NSCLC"). AZD9291 is ... receptor (EGFR). Preliminary data on the activity of ...
(Date:5/31/2015)... June 1, 2015 Sobi, ... diseases, has selected Veeva Commercial Cloud to support ... medical. A complete solution, Veeva Commercial Cloud ... compliant content to provide a comprehensive view of ...      (Logo: http://photos.prnewswire.com/prnh/20120425/527164) , ...
(Date:5/31/2015)... , May 31, 2015 Halozyme ... company developing novel oncology and drug-delivery therapies, today ... clinical study of its investigational new drug PEGPH20 ... pancreatic cancer. The encouraging interim data ... Clinical Oncology annual meeting in an oral presentation ...
(Date:5/30/2015)... May 30, 2015 The Cholangiocarcinoma ... research for bile duct cancer, announced today the ... Fellowship Program. , The Foundation has ... throughout the country to raise awareness about cholangiocarcinoma ... support research that opens new pathways for diagnosis ...
Breaking Biology Technology:Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 2Savolitinib (AZD6094) Preliminary Phase Ib Clinical Data in Lung Cancer Presented at the 2015 ASCO Annual Meeting 3Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 2Sobi Establishes Global Commercial Operations in the Cloud with Best-in-Class Veeva Commercial Cloud 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 2Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 3Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 4Halozyme Phase 2 Clinical Study Of Investigational Drug PEGPH20 Shows Doubling Of Progression-free Survival And Improvement Trend In Overall Survival In High HA Metastatic Pancreatic Cancer Patients 5The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 2The Cholangiocarcinoma Foundation Awards $260,000 in Research Grants 3
... , ... marks the increasing popularity of open source software (OSS) in clinical trial electronic data ... ... OpenClinica, the rapidly growing open source clinical trial software, will gather on March 22nd, ...
... ... biopharmaceutical company focused on the development of novel vaccine candidates to treat chronic viral ... conference and will be attending the J.P. Morgan Healthcare Conference in San Francisco. ... Baltimore, MD (Vocus) ...
... ... QT Beat-to-Beat(sm) to Improve Precision and Reduce Risk of False Positives/Negatives , ... Rochester, New York (PRWEB) January ... and QT analysis, announced today that a leading global CRO has selected iCardiac as ...
Cached Biology Technology:OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 2OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 3OpenClinica Global Conference to Bring Together Global Community for Open Source Clinical Trials Software 4Profectus Biosciences to Present at Key Investor Conference in January 2010 2Profectus Biosciences to Present at Key Investor Conference in January 2010 3Leading Global CRO Selects iCardiac as Preferred Vendor 2
(Date:5/25/2015)... 2015  Australia,s market for wearable technologies is considered ... the advent of several trials and prototypes. The release ... expected to ignite interest in wearables as well as ... . This in turn will spur greater innovation ... partnerships amongst vendors and distributors. Photo ...
(Date:5/20/2015)... , May 20, 2015 ... ) has announced the addition of ... Global Iris Recognition Market"  report to ... ,This research service analyses trends in ... government and commercial sectors, globally. Despite ...
(Date:5/18/2015)... GOTHENBURG, Sweden , May 18, 2015 ... touch fingerprint sensors FPC1020, FPC1025, FPC1145, FPC1155 and FPC1035 from ... place from June until and including Q3 2015 and the ... Asia . Communicated order values for 2015 hereby amount ... revenues for Q1 2015 of 140 MSEK and a number ...
Breaking Biology News(10 mins):Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 2Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 3Australian wearables market to grow at CAGR of 78%; revenue of A$1 billion by 2018, says Frost & Sullivan 4Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2
... release is available in German . 48 healthy ... at the start of the experiment, the other half a placebo. ... situations in the form of a crying child, a girl hugging ... invited to express the depth of feeling they experienced for the ...
... skin crawla bug that crawls onto your lips while you ... bites, then gorges on your blood. And if that,s not ... a potentially deadly disease. Now Jean-Paul Paluzzi, a ... believes that manipulating physiology to prevent the insects from leaving ...
... an effective way of tackling global warming despite emitting small ... Research led by the University of Edinburgh suggests that ... the Earth,s emissions of methane which is considered to be ... warming. The results contrast with a previous scientific study ...
Cached Biology News:Hormone spray improves male sensitivity 2The kiss of death: Research targets lethal disease spread by insect that bites lips 2
Tracker Datamatrix TRxD reads any 1D and 2D barcodes within 0.5 seconds....
Complete cell culture media with cytokines...
... BioChain's monkey normal multiple tissue ... specific cellular localization of genes or ... tissues. Tissues are mounted on positively ... Blots are available in the identical ...
8 different frozen tissues are mounted on positively charged glass slides...
Biology Products: